

**REMARKS**

Applicant hereby submits claims 22-30, to replace claims 1, 5-12, and 21 previously considered by the Examiner. A new claim 31, has been added.

We hereby provide a detailed account for the support of the amendments to the claims as well as our arguments in response to the Examiner's objections.

With respect to the limitation of the claims to the treatment and prevention of systemic inflammatory response syndrome (SIRS) we refer to the review article of Nyström entitled "The Systemic Inflammatory Response Syndrome: definitions and Aetiology," (enclosed), which deals with the definitions and etiology of SIRS. The introduction of this article cites as reference 1 the reference of Bone et al., a reference that is also cited in paragraph 4 of the published application.

*"The introduction of the term 'systemic inflammatory response syndrome' (SIRS) by the American College of Chest Physicians and Society of Critical Care Medicine (ACCP/SCCM) consensus conference<sup>1</sup> recognised the important role that endogenous mediators of systemic inflammation play in 'sepsis', which was no longer regarded as being caused by microbial pathogenicity factors alone."*

Table III on page 3 of the Nyström article, presents the definition of SIRS and indicates well that sepsis is a SIRS as it has two of the conditions mentioned in the definition of SIRS.

*"SIRS : the systemic inflammatory response to a variety of severe clinical insults. The response is manifested by two or more of the following conditions: temperature > 38°C or < 36°C; heart rate > 90 beats/min; respiratory rate > 20 breaths/min or PaCO<sub>2</sub> < 32 torr ( < 4.3 kPa); WBC > 12,000 cells/mm<sup>3</sup>, < 4000 cells/mm<sup>3</sup> or > 10% immature (band) forms"*

"Sepsis : the systemic *response* to infection; this response is manifested by two or more of the SIRS criteria as a result of infection"

Consequently, it is respectfully submitted that sepsis is a condition resorting under the general term SIRS and the treatment and/or prevention of sepsis can thus be seen as a particular embodiment of the claims as presently amended.

#### 1. Amendments

With reference to the listing of claims, new claims 22 to 30 correspond to the subject matter previously claimed in claims 5-12 and 21.

Present claim 22, corresponds to previous claim 1, but has been amended as follows:

- the claim now refers to SIRS (systemic inflammatory response syndrome) and no longer cites different diseases.
- The claim now refers to 'a monoclonal antibody a monoclonal antibody against Factor VIII or an antigen binding fragment of said monoclonal antibody
- the limitation of previous claim 7, which specified binding to the C1 domain of factor VIII has been introduced.

Support in the description for the amendments in claim 22 is found in

- paragraph 14:

*"The present invention first provides a method for preventing and/or treating a systemic inflammatory response syndrome (SIRS) in mammals by (i.e. the said method comprising or, preferably, consisting essentially of) partially inhibiting the formation of thrombin, for instance by administering a partial inhibitor of factor VIII to the mammal in need thereof.*

- paragraph 14:

*"In the various above-mentioned aspects of the present invention, the partial inhibitor of factor VIII may be a ligand, preferably other than a polyclonal antibody, more preferably a **monoclonal antibody or antigen-binding fragment thereof**...(emphasis added)*

- paragraph 38:

*"The present invention also provides **fragments of any of the above monoclonal antibodies** [...]. More particularly, these **monoclonal antibodies and fragments may target a domain of factor VIII, in particular the C1 domain of factor VIII**"(emphasis added)*

Previous claims 6, 8 and 10, 12 and 21 have been reordered into present claims 25, 23-24, 26, 28 and 29, respectively.

Claim 27 (Previous claim 5) has been amended to refer only to the monoclonal antibody obtainable from the deposited cell line.

Claim 28 corresponds to previous claim 11, but has been limited to certain types of fragments, particularly considered in the context of the present invention. Moreover the claim has been limited to fragments obtainable from the deposited cell line.

Support in the description for claim 28 can be found in paragraph 38:

*"The present invention also provides **fragments of any of the above monoclonal antibodies such as Fab, Fab', F(ab').sub.2, scFv**, [...].*

New claim 30 relates to a specific embodiment of the invention, whereby the antibodies have at least 80% sequence identity with the antibodies obtainable from the deposited cell line. Support for new claim 30 can be found in paragraph 31 (of the published application):

*"Where the said ligands include amino-acid sequences, then, homology should include having at least 80%, more*

*preferably 90% and most preferably 95% amino acid sequence identity with the relevant ligand".*

and especially in paragraph 48:

*"Most preferably the said monoclonal antibody is a human monoclonal antibody, or a fragment or a **homologue thereof**, obtainable from the cell line KRIX 1 deposited with the Belgian Co-ordinated Collections of Micro-organisms under accession number LMBP 5089CB. The degree of homology with the said monoclonal antibody is preferably at least 80%, more preferably 90% and most preferably 95%, and the homology is preferably particularly in respect to the complementarity determining regions of the antibody"*

## 2. Objections presented in the Office Action

### a) Objection under 35 U.S.C.112, second paragraph (items 6-7 of the Office Action)

It is respectfully submitted that the removal of the reference to "having a reactivity substantially identical to" in the amended claims filed herewith, should render this objection moot

Moreover, the objection to previous claim 8 has been overcome by inserting the subject matter of claim 8 in two separate claims, as has been done in present claims 23 and 24.

### b) Objection under 35 U.S.C.112, first paragraph (items 9 of the Office Action)

The KRIX-1 cell line has been deposited by one of the inventors (Dr. M. Jacquemin) in a recognized depository institution resorting under the Budapest Treaty as mentioned in the specification of the published application on page 4, paragraph 39:

*"The cell line named KRIX 1 producing monoclonal antibodies as used in the present invention was deposited with the BCCM.TM./LMBP (Belgian Co-ordinated collections of Microorganisms/Plasmid Collection*

*Laboratorium voor Moleculaire Biologie, University of Ghent K. L. Ledeganckstraat 35, B-9000 Ghent, BE under accession number LMBP 5089CB on Jul. 1, 1999”.*

The deposit is thus present in a public depository and in accordance with rule 9.1 of the Budapest Treaty. A copy of the receipt provided to Applicant by the BCCM indicating that this deposit was received under the Budapest Treaty, as well as the requested statement with regard to its availability are attached. We enclose a declaration of the inventor certifying the availability of the deposit. Given this statement and Applicant's Declaration, Applicant submits that this part of the rejection should therefore be withdrawn.

With regard to the further objections made with regard to the enablement of the claims, it is respectfully submitted that the amended claims as filed herewith now refer to inhibitory antibodies and fragments with defined binding properties (against the C1 domain of FVIII).

We submit that the specification clearly provides enablement for a method for preventing and/or treating SIRS by administering an antibody to the C1 domain of FVIII or an antigen-binding fragment thereof, and that thus the description is commensurate in scope with the broadest claim presently submitted. Indeed the Examiner has acknowledged the enablement of the description for ‘anti-FVIII C1 domain’ antibodies and more particularly for the antibody produced by the deposited KRIX-1 cell-line. Thus, this amendment should render the Examiner’s objections made in the three last paragraphs of page 4 of the office action moot.

The Examiner has moreover brought the argument that *in vitro* studies do not correlate well with *in vivo* clinical trial results in patients and thus questions the reliability of the data obtained *in vitro* with the antibodies of the present invention as enabling disclosure.

Without acquiescence of the Examiner’s objection, we hereby submit a declaration from one of the inventors, dr. Jean-Marie Saint-Rémy, which provide additional *in vivo* data of an anti- FVIII C1 domain antibody, which is a partial inhibitor of FVIII in mice, and demonstrate that it can be administered in elevated dosages without the side-effects typically observed for complete FVIII inhibitors and that it is capable of preventing LPS-induced shock in a well established mouse model. Thus, the *in vitro* thrombin formation demonstrated for anti-FVIII C1 domain antibodies

can be considered to be representative for an *in vivo* partial inhibition and, more importantly, for a therapeutic application of these antibodies in the treatment and prevention of SIRS.

The examiner has indicated in the Office action on page 5, third paragraph that there may be a concern for bleeding as a result of the inhibition of FVIII. It is respectfully submitted that this is exactly one of the major features of the present invention as specified in the claims, i.e. the antibodies are only partially inhibitory so that, regardless of the concentration being used, a residual activity of FVIII is maintained. A consequence of this feature (also referred to as 'plateau effect' is that there is always a sufficiently high level of FVIII to avoid the bleeding disorders which would occur with complete FVIII inhibition.

The Examiner has moreover referred to a publication by Taylor et al. (1997), to demonstrate the lack of correlation sometimes observed between *in vivo* data in animals and what occurs in humans. The article of Taylor deals with a combination of C4bBP and living *E. coli* bacteria as a model for human diffuse intravascular coagulation, thrombotic thrombocytopenic purpura, and hemolytic uremic syndrome. This syndrome induced by the combination of C4bBP and *E. coli* and, the author states in the article, it has "**elements that are similar** to those observed in [diffuse intravascular coagulation, thrombotic thrombocytopenic purpura, and hemolytic uremic syndrome]" (page 4078, left column, line (emphasis added)). Further on in the article, it is also mentioned that the platelets "**at least in part** mediate the tissue damage associated with these syndromes]" (page 4078, left column, line 17-19 (emphasis added). (emphasis added).

Thus, Taylor himself indicates that the C4bBP + *E. coli* treatment only partially mimics the mentioned disorders and based thereon concludes that a treatment at the level of platelet aggregation will be only a partial solution for curing these disorders.

This notion of the fact that a non-perfect model was used for the disorders studied, is also mentioned at the end of the discussion of the article. From this it can be deduced that Taylor ascribes the differences in the pathophysiology between model and disease not to the differences between baboon and man but rather to the differences between the model and the disorders themselves. We submit that the Taylor article at most suggests that it is difficult to extrapolate from a model which in his opinion only reflects some aspects of the actual disease as observed in

humans, and it is submitted that the article gives no warnings of extrapolating baboon results to humans.

In this context it is noteworthy that the C4bBP protein, referred to in the Taylor et al. publication is reported to lead to inhibition of Protein C. It is precisely this inhibition which is prevented in the present invention, as partial inhibition of Factor VIII makes it possible to preserve Protein C activity. This further stresses major differences between the cited article and the present invention.

With respect to the enablement rejection, the examiner is directed to MPEP § 2164.02 setting for the standard for evaluating the correlation between the animal model and the method of use. "...if the art is such that a particular model is recognized as correlating to a specific condition then it should be accepted as correlating unless the examiner has evidence the model does not correlate". We moreover respectfully submit that the animal model used in the *in vivo* experiments described in the application or those presented in the declaration submitted herewith is a well-established model for sepsis.

It is respectfully submitted that the objections raised under 35 U.S.C 112, first paragraph under item 10 of the Office Action should also be rendered moot by the amendments to the claims, whereby the scope has been restricted to the use of monoclonal anti-FVIII C1 domain antibodies, and the *in vivo* data demonstrating the fact that indeed these monoclonal anti-FVIII C1 domain antibodies have therapeutic application in the prevention and/or treatment of sepsis.

The limitation of the claims relating to the use of a partial inhibitor of FVIII to the antibodies which bind to the C1 domain of FVIII provides a clear functional description of the antibodies of the invention. This specification provides clear written description on how such antibodies can be obtained. As antibodies are generally defined and identified by their binding properties and not by their actual molecular structure, it is submitted that the determination of these specific binding properties corresponding to the genus and how antibodies falling within this genus can be selected for as provided in the specification provides sufficient written description to demonstrate that the applicant was in possession of the genus.

In view of the amendments and remarks, the application is now in condition for allowance and favorable consideration is requested.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Peter J. Shakula', with a long horizontal flourish extending to the right.

Peter J. Shakula  
Registration No. 40,808

BARNES & THORNBURG  
One North Wacker Drive  
Suite 4400  
Chicago, IL 60606-2809  
(312) 214-4813  
Dated: October 21, 2004



**BELGIAN COORDINATED COLLECTIONS OF MICROORGANISMS - BCCM™  
LMBP-COLLECTION**

Page 1 of Form BCCM™/LMBP/BP/4/99-14 Receipt in the case of an original deposit

**Budapest Treaty on the International Recognition of the Deposit of Microorganisms for  
the Purposes of Patent Procedure**

Receipt in the case of an original deposit issued pursuant to Rule 7.1 by the  
International Depositary Authority BCCM™/LMBP identified at the bottom of next page

**International Form BCCM™/LMBP/BP/4/99-14**

To: Name of the depositor : JACQUEMIN MARC

Address : Center for Molecular and Vascular Biology  
Onderwijs & Navorsing  
Herestraat 49  
3000 Leuven

**I. Identification of the microorganism:**

**I.1 Identification reference given by the depositor:**

KRIX 1

**I.2 Accession number given by the International Depositary Authority:**

LMBP 5089CB

02447005.6

**BELGIAN COORDINATED COLLECTIONS OF MICROORGANISMS - BCCM™  
LMBP-COLLECTION**

Page 1 of Form BCCM™/LMBP/BP/9/99-14 Viability statement

**Budapest Treaty on the International Recognition of the Deposit of Microorganisms for  
the Purposes of Patent Procedure**

**Viability statement issued pursuant to Rule 10.2 by the International Depositary  
Authority BCCM™/LMBP identified on the following page**

**International Form BCCM™/LMBP/BP/9/99-14**

**To : Party to whom the viability statement is issued:**

**Name : JACQUEMIN MARC**

**Address : Center for Molecular and Vascular Biology  
Onderwijs & Navorsing  
Herestraat 49  
3000 Leuven**

**I. Depositor:**

**I.1 Name : JACQUEMIN MARC**

**I.2 Address : Center for Molecular and Vascular Biology  
Onderwijs & Navorsing  
Herestraat 49  
3000 Leuven**

**II. Identification of the microorganism:**

**II.1 Accession number given by the International Depositary Authority:**

**LMBP 6089CB**

**II.2 Date of the original deposit (or where a new deposit or a transfer has been  
made, the most recent relevant date) : July 1, 1999**

**III. Viability statement.**

**The viability of the microorganism identified under II above was tested on**

**: July 9, 1999**

**(Give date. In the cases referred to in Rule 10.2(a)(ii) and (iii), refer to the most recent  
viability test).**

**On that date, the said microorganism was: (mark the applicable box with a cross)**


☒ **viable**

☐ **no longer viable**

US Application No. 10/044,569  
Inventors: M. Jacquemont & J.M. Saint Rémy

### STATEMENT

The Krix-1 cell line has been deposited with the Belgian Coordinated collections of Microorganisms (BCCM) on July 1<sup>st</sup>, 1999 and bears the accession number 1468 5089CB. Applicants acknowledge their responsibility to replace this strain should it lose viability before the end of the term of a patent issued hereon, and their responsibility to notify the BCCM of the issuance of such a patent, at which time the deposit will be made available to the public. Prior to that time the deposit will be made available to the Commissioner of Patents under terms of CFR §1.14 and 35 USC §112.

  
Dr. Marc Jacquemont

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**